José M. Gatell

21.9k total citations · 7 hit papers
218 papers, 13.5k citations indexed

About

José M. Gatell is a scholar working on Infectious Diseases, Virology and Emergency Medicine. According to data from OpenAlex, José M. Gatell has authored 218 papers receiving a total of 13.5k indexed citations (citations by other indexed papers that have themselves been cited), including 165 papers in Infectious Diseases, 151 papers in Virology and 67 papers in Emergency Medicine. Recurrent topics in José M. Gatell's work include HIV Research and Treatment (150 papers), HIV/AIDS drug development and treatment (137 papers) and HIV/AIDS Research and Interventions (111 papers). José M. Gatell is often cited by papers focused on HIV Research and Treatment (150 papers), HIV/AIDS drug development and treatment (137 papers) and HIV/AIDS Research and Interventions (111 papers). José M. Gatell collaborates with scholars based in Spain, United Kingdom and United States. José M. Gatell's co-authors include Patrick Yéni, Robert T. Schooley, Donna M. Jacobsen, Melanie Thompson, Martin Hirsch, Douglas D. Richman, Paul A. Volberding, Scott M. Hammer, Joan Montaner and Margaret A. Fischl and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

José M. Gatell

216 papers receiving 13.0k citations

Hit Papers

Antiretroviral Therapy in... 2000 2026 2008 2017 2000 2008 2006 2004 2010 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Antiretroviral Therapy in Adults
    2000 874 citations José M. Gatell, Stefano Vella et al. profile →
  2. Antiretroviral Treatment of Adult HIV Infection
    2008 832 citations Peter Reiss, José M. Gatell et al. profile →
  3. Treatment for Adult HIV Infection
    2006 767 citations Mauro Schechter, José M. Gatell et al. profile →
  4. Treatment for Adult HIV Infection
    2004 601 citations Mauro Schechter, José M. Gatell et al. profile →
  5. Antiretroviral Treatment of Adult HIV Infection
    2010 595 citations José M. Gatell, Peter Reiss et al. profile →
  6. Antiretroviral Treatment for Adult HIV Infection in 2002
    2002 573 citations José M. Gatell, Mauro Schechter et al. profile →
  7. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial
    2007 453 citations José M. Gatell et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
José M. Gatell Spain 53 10.3k 8.0k 3.4k 3.3k 1.1k 218 13.5k
Paul E. Sax United States 58 9.6k 0.9× 7.0k 0.9× 4.6k 1.3× 3.4k 1.0× 1.5k 1.4× 244 14.2k
Joel E. Gallant United States 56 11.9k 1.2× 9.7k 1.2× 3.4k 1.0× 4.3k 1.3× 1.8k 1.6× 156 15.8k
Stefano Vella Italy 53 10.4k 1.0× 8.2k 1.0× 2.2k 0.6× 3.5k 1.1× 711 0.7× 247 13.6k
Eric S. Daar United States 55 7.3k 0.7× 7.2k 0.9× 2.5k 0.7× 2.9k 0.9× 1.6k 1.5× 239 11.5k
Melanie Thompson United States 46 10.4k 1.0× 7.4k 0.9× 2.5k 0.7× 3.6k 1.1× 466 0.4× 112 12.9k
Ann C. Collier United States 65 9.1k 0.9× 9.1k 1.1× 3.0k 0.9× 3.3k 1.0× 1.4k 1.3× 256 14.9k
Matthias Cavassini Switzerland 58 7.8k 0.8× 5.0k 0.6× 3.0k 0.9× 3.7k 1.1× 868 0.8× 367 11.8k
Anton Pozniak United Kingdom 53 8.2k 0.8× 5.2k 0.7× 1.9k 0.5× 3.5k 1.1× 768 0.7× 294 10.7k
Joep M. A. Lange Netherlands 62 9.2k 0.9× 9.3k 1.2× 2.0k 0.6× 3.3k 1.0× 2.4k 2.2× 293 14.2k
Roy M. Gulick United States 50 8.3k 0.8× 6.7k 0.8× 1.6k 0.5× 1.9k 0.6× 746 0.7× 168 10.6k

Countries citing papers authored by José M. Gatell

Since Specialization
Citations

This map shows the geographic impact of José M. Gatell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by José M. Gatell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites José M. Gatell more than expected).

Fields of papers citing papers by José M. Gatell

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by José M. Gatell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by José M. Gatell. The network helps show where José M. Gatell may publish in the future.

Co-authorship network of co-authors of José M. Gatell

This figure shows the co-authorship network connecting the top 25 collaborators of José M. Gatell. A scholar is included among the top collaborators of José M. Gatell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with José M. Gatell. José M. Gatell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lazzari, Elisa de, Peré Domingo, Juan Tiraboschi, et al.. (2024). Multiomics plasma effects of switching from triple antiretroviral regimens to dolutegravir plus lamivudine. Journal of Antimicrobial Chemotherapy. 79(5). 1133–1141. 1 indexed citations
2.
Fabra-García, Amanda, María Casadellà, Marc Noguera-Julián, et al.. (2018). Guiding the humoral response against HIV-1 toward a MPER adjacent region by immunization with a VLP-formulated antibody-selected envelope variant. PLoS ONE. 13(12). e0208345–e0208345. 8 indexed citations
3.
Gatell, José M., Lambert Assoumou, Graeme Moyle, et al.. (2017). Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk. AIDS. 31(18). 2503–2514. 54 indexed citations
4.
5.
Torres, Berta, Norma Rallón, Montserrat Loncà, et al.. (2013). Immunological Function Restoration with Lopinavir/Ritonavir Versus Efavirenz Containing Regimens in HIV-Infected Patients: A Randomized Clinical Trial. AIDS Research and Human Retroviruses. 30(5). 425–433. 8 indexed citations
6.
Guardo, Alberto C., María J. Maleno, Marta Calvo, et al.. (2012). In vitro effects of the CCR5 inhibitor maraviroc on human T cell function. Journal of Antimicrobial Chemotherapy. 68(3). 577–586. 33 indexed citations
7.
Miró, José M., Frederic Cofán, Joan Carles Trullàs, et al.. (2012). Renal Dysfunction in the Setting of HIV/AIDS. Current HIV/AIDS Reports. 9(3). 187–199. 21 indexed citations
8.
Castro, Pedro, Montserrat Plana, Raquel González, et al.. (2012). Influence of Episodes of Intermittent Viremia (“Blips”) on Immune Responses and Viral Load Rebound in Successfully Treated HIV-Infected Patients. AIDS Research and Human Retroviruses. 29(1). 68–76. 19 indexed citations
9.
Martínez, Estebán, et al.. (2012). Abacavir/Lamivudine Versus Tenofovir/Emtricitabine in Virologically Suppressed Patients Switching from Ritonavir-Boosted Protease Inhibitors to Raltegravir. AIDS Research and Human Retroviruses. 29(2). 235–241. 11 indexed citations
10.
Gómez, Carmen, José Luis Nájera, Beatriz Perdiguero, et al.. (2011). The HIV/AIDS Vaccine Candidate MVA-B Administered as a Single Immunogen in Humans Triggers Robust, Polyfunctional, and Selective Effector Memory T Cell Responses to HIV-1 Antigens. Journal of Virology. 85(21). 11468–11478. 59 indexed citations
11.
Blanco, J. L., Vici Varghese, Soo‐Yon Rhee, José M. Gatell, & Robert W. Shafer. (2011). HIV-1 Integrase Inhibitor Resistance and Its Clinical Implications. The Journal of Infectious Diseases. 203(9). 1204–1214. 175 indexed citations
12.
13.
Castro, Pedro, Montserrat Plana, Raquel González, et al.. (2009). Influence of a Vaccination Schedule on Viral Load Rebound and Immune Responses in Successfully Treated HIV-Infected Patients. AIDS Research and Human Retroviruses. 25(12). 1249–1259. 22 indexed citations
14.
Mestre, Gabriel, Felipe García, Estebán Martínez, et al.. (2008). Short Communication: Natural Killer Cells and Expression of KIR Receptors in Chronic HIV Type 1-Infected Patients after Different Strategies of Structured Therapy Interruption. AIDS Research and Human Retroviruses. 24(12). 1485–1495. 5 indexed citations
15.
Moyle, Graeme, José M. Gatell, Carlo Federico Perno, et al.. (2008). Potential for New Antiretrovirals to Address Unmet Needs in the Management of HIV-1 Infection. AIDS Patient Care and STDs. 22(6). 459–471. 22 indexed citations
16.
Castro, Pedro, Montserrat Laguno, Meritxell Nomdedéu, et al.. (2007). Clinicoimmunological Progression and Response to Treatment of Long-Term Nonprogressor HIV–Hepatitis C Virus-Coinfected Patients. AIDS Research and Human Retroviruses. 23(7). 863–867. 4 indexed citations
17.
Libois, Agnès, Anna Lena Lopez, Felipe García, et al.. (2006). Dynamics of T Cells Subsets and Lymphoproliferative Responses During Structured Treatment Interruption Cycles and After Definitive Interruption of HAART in Early Chronic HIV Type-1-Infected Patients. AIDS Research and Human Retroviruses. 22(7). 657–666. 13 indexed citations
18.
Walker, Ulrich A., Jochen Bäuerle, Montse Laguno, et al.. (2004). Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine. Hepatology. 39(2). 311–317. 123 indexed citations
19.
Mocroft, Amanda, José M. Gatell, Peter Reiss, et al.. (2004). Causes of death in HIV infection. AIDS. 18(17). 2333–2337. 30 indexed citations
20.
Martínez, Estebán, José M. Gatell, E. Ubiña Aznar, et al.. (1998). High Incidence of Herpes Zoster in Patients with AIDS Soon After Therapy with Protease Inhibitors. Clinical Infectious Diseases. 27(6). 1510–1513. 103 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Paul E. Sax Breakdown of academic impact, for papers by Joel E. Gallant Breakdown of academic impact, for papers by Stefano Vella Breakdown of academic impact, for papers by Eric S. Daar Breakdown of academic impact, for papers by Melanie Thompson Breakdown of academic impact, for papers by Ann C. Collier Breakdown of academic impact, for papers by Matthias Cavassini Breakdown of academic impact, for papers by Anton Pozniak Breakdown of academic impact, for papers by Joep M. A. Lange Breakdown of academic impact, for papers by Roy M. Gulick
Rankless by CCL
2026